**INTRODUCTION**

Drug-induced liver injury (DILI) is the most frequent cause of safety-related postmarketing drug withdrawals [1, 2] and is the most common reason for acute liver failure in the United States [3, 4]. DILI shares many clinical features with other forms of liver injury, making a definitive DILI diagnosis challenging [3]. A DILI diagnosis is usually determined by ruling out other common forms of liver injury, such as gall bladder disease, malignancy, and concomitant hepatotoxic drugs [2, 3]. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin are routinely measured in clinical trials to detect potential signals of drug-induced liver abnormalities. Drug-induced elevations in aminotransferases >3 × the upper limit of normal (ULN) in combination with total bilirubin elevations >2 × ULN have been termed "Hy's law", and may be indicative of severe hepatocellular injury and DILI [2]. However, a number of drugs can cause transient aminotransferase elevations without progressing to severe liver injury (e.g., aspirin, statins, heparin) [2], and genetic factors can predispose some individuals to hyperbilirubinemia.

The uridine diphosphate (UDP) glucuronosyltransferase family 1 member A1 gene (*UGT1A1*) encodes the enzyme UDP-glucuronosyltransferase 1-1, responsible for the conjugation of bilirubin and glucuronic acid, forming a water-soluble glucuronide that is excreted into the bile [5]. Genetic variation in *UGT1A1* has been linked to Gilbert's syndrome, a common benign condition characterized by elevations in unconjugated bilirubin and jaundice in the absence of aminotransferase elevations. The underlying genetic variation responsible for the majority of cases has been identified as a TA repeat polymorphism (*UGT1A1*^*28* allele) located in the promoter region [6]. *UGT1A1*^*28* carriers have seven copies of the TA repeat polymorphism [A(TA)7TAA] and ~70% reduced *UGT1A1* gene expression versus individuals with the more common allele featuring six copies of the TA repeat [A(TA)6TAA] [5]. Gilbert's syndrome patients are typically homozygous carriers of the *UGT1A1*^*28* allele, and have lower *UGT1A1* gene expression and diminished bilirubin metabolism. Other variants have been identified that influence *UGT1A1* function and are associated with Gilbert's syndrome but are less common than the *UGT1A1*^*28* allele [5, 7].

Sarilumab is a human monoclonal antibody against interleukin (IL)-6Ra that has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) and an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Mild liver function test abnormalities have been observed in patients treated with sarilumab. We describe a genome-wide association study of bilirubin elevations in RA patients treated with sarilumab. Array genotyping and exome sequencing were performed on DNA samples from 1075 patients. Variants in the *UGT1A1* gene were strongly associated with maximum bilirubin elevations in sarilumab-treated patients (rs4148325; \( p = 2.88 \times 10^{-41} \)) but were not associated with aminotransferase elevations. No other independent loci showed evidence of association with bilirubin elevations after sarilumab treatment. These findings suggest that most bilirubin increases during sarilumab treatment are related to genetic variation in *UGT1A1* rather than underlying liver injury.

The Pharmacogenomics Journal (2022) 22:160–165; https://doi.org/10.1038/s41397-022-00269-5
allele and increases in unconjugated bilirubin levels [11, 12]. We retrospectively tested if UGT1A1 variants were associated with bilirubin elevations in sarilumab-treated patients, and performed a genome-wide association study (GWAS) to explore if any genetic variants outside of the UGT1A1 locus were associated with bilirubin elevations. Understanding the role common UGT1A1 genetic variation may play in serum bilirubin elevations in sarilumab-treated patients may allow physicians to more clearly differentiate true Hb’s law cases from false positives.

SUBJECTS AND METHODS

Study population

The pharmacogenomic study population included patients from three clinical trials: MOBILITY (NCT01061736) [13], TARGET (NCT01709578) [14], and ASCERTAIN (NCT01768572) [15]. These studies were randomized, double-blind, parallel-group trials investigating the efficacy and/or safety of sarilumab in adults with moderately to severely active RA. Inclusion criteria for disease history and severity were similar across studies. MOBILITY used the American College of Rheumatology (ACR) 1987 Rheumatoid Arthritis Classification Criteria to diagnose RA, while TARGET and ASCERTAIN used ACR/European League against Rheumatism 2010 Rheumatoid Arthritis Classification Criteria.

All study protocols were approved by the appropriate ethics committees/institutional review boards. A separate written informed consent was provided by patients who participated in the optional pharmacogenomics substudy. The details were conducted in compliance with institutional review board regulations, the International Conference on Harmonization Guidelines for Good Clinical Practice, and the Declaration of Helsinki.

Genotype and whole-exome sequencing data

Patient DNA samples underwent microarray genotyping and whole-exome sequencing. Two microarray platforms were used in these studies. The Illumina Infinium Human OmniExpress Exome Bead Chip, v1.2 (Illumina Inc., San Diego, CA, USA) generated microarray genotypes for samples from MOBILITY and TARGET. The Illumina Global Screening Array v1.0 genotyped samples from TARGET and ASCERTAIN. Additional genetic data were generated via whole-exome sequencing. DNA samples from MOBILITY underwent exome capture using the NimbleGen VCRome, while exome capture for DNA samples from TARGET and ASCERTAIN was conducted using the IIT xGen v1.0 kit. For all studies, sequencing was performed using Illumina HiSeq 2500 instruments. All whole-exome sequencing and microarray genotyping were conducted by the Regenzer Genetics Center.

Identical quality control (QC) metrics were applied to variants genotyped on the Illumina Infinium Human OmniExpress Exome array and the Illumina Global Screening Array. The call rates (% of nonmissing genotypes) by variant and by sample were calculated. Genetic variants with a call rate <90% were excluded from further statistical analyses. Individual samples with a call rate <90%, or discordance between genetically determined sex and sex in the clinical database, were removed from further analyses. Additionally, relatedness between all study participants was evaluated. Paired samples with estimated identity-by-descent ≥0.1875 were flagged as potential duplicates/familial relationships; the sample with the lower call rate was removed from the analysis.

Hardy–Weinberg equilibrium (HWE) tests were calculated in the major genetically determined ancestry subgroups. Viants with significant deviations from HWE (p < 1 × 10−5) were removed from the analysis. Genotype imputation with array data was used to infer additional genotypes using the program Minimac4 through the Michigan Imputation Server [16]. Reference populations for imputation were obtained from the 1000 Genomes phase 3 version 5 data [17]. Additional QC measures were applied to imputed genotypes, including a minor allele frequency ≥1%, missingness < 0.1, and estimated imputation r² (rsq-hat) ≥ 0.3.

Population structure was assessed using principal components analysis (PCA) with PLINK software (versions 1.9 and 2) [18]. Each patient was assigned to one of five major ancestral classes (African, Admixed American, East Asian, European, or South Asian) based on the similarity between each patient’s genotypes and genetic data from the International HapMap project. Principal components were calculated for each of the HapMap groups of known ancestry. A kernel density estimate was trained for each ancestral class, and the likelihood of each patient belonging to one of the five major classes was calculated to assign ancestral class.

Statistical analysis

Due to the small patient numbers in each study, data were pooled, and all analyses included a covariate for study group. Unless otherwise specified, all postbaseline analyses were stratified by treatment group (i.e., placebo + DMARD or sarilumab + DMARD).

The primary purpose of this analysis was to describe a genome-wide association of bilirubin elevation in RA patients treated with sarilumab. The analysis endpoints included total bilirubin (mg/dl), unconjugated bilirubin (mg/dl), conjugated bilirubin (mg/dl), ALT (ukat/l), and AST (ukat/l) and alkaline phosphatase (ALP). All endpoints were measured longitudinally over the 24-week study periods, at 2-week intervals during the first 12 weeks and at 4-week intervals thereafter. All patients had microarray genotyping at the baseline study visits. Following the clinical study statistical analysis methods, the last observation carried forward approach was used to impute postbaseline missing values. During the clinical trials, drug treatment was discontinued in cases of ALT > 5 × ULN or ALT > 3 × ULN and concomitant total bilirubin > 2 × ULN (unless the patient had documented Gilbert’s syndrome), however, no cases of Hb’s law were observed [16]. In cases of ALT ≥ 3 × but ≤ 5 × ULN and bilirubin ≥ 2 × ULN, treatment was withheld, and ALT/AST and bilirubin levels were measured within 48 h of the original laboratory results.

In the GWAS analysis, a linear regression model was used to evaluate the association between each endpoint and variant genotypes. The model included study, gender, age, baseline measurement (in all postbaseline analyses), and the first eight PCA scores as covariates. Due to the skewed distribution observed for maximum bilirubin, this endpoint was transformed with a rank inverse normal transformation prior to genetic analysis.

To assess the association between each endpoint and candidate variants in the UGT1A1 gene region, we applied functional canonical correlation analysis (FCCA). The mathematical and computational details of FCCA have been described previously [19]. In this analysis, the variant is treated as the exposure (study group), and the outcome is the phenotype to be associated with genotypes. After the association between the candidate variants in UGT1A1 and ULN-dichotomized total bilirubin level in sarilumab-treated patients; covariate adjustment was performed to account for other factors. To further investigate the total bilirubin elevation in sarilumab-treated patients, total bilirubin level was dichotomized into two categories by the ULN level (≤ 1.5 × ULN or > 1.5 × ULN; 1.5 × ULN of total bilirubin corresponds to 1.84 mg/dl). Fisher’s exact test was applied to confirm results of any Firth regression models.

RESULTS

A total of 1075 patients (642, 368, and 65 from MOBILITY, TARGET, and ASCERTAIN, respectively) provided DNA and consented to participate in the pharmacogenomics analysis. Patients’ ancestry was determined using principal components as shown in Supplementary Figure 1. In total, 55% of patients were assigned European ancestry, 36% were assigned Admixed American ancestry (due to a large number of clinical sites in South and Central America), and 2% were assigned to other ancestries (Table 1). At baseline, patients from MOBILITY and TARGET had similar levels of bilirubin and transaminases. Patients from ASCERTAIN had slightly higher levels of bilirubin at baseline, but they represented only 6% of the patients in the pharmacogenomic analysis. Due to the treatment allocation design of the clinical trials, 755 (70%) patients were treated with sarilumab + DMARD, while 320 (30%) patients were treated with placebo + DMARD.
Associations between bilirubin levels and UGT1A1 variants

The GWAS of maximum bilirubin levels during the study period in patients treated with sarilumab + DMARD identified a strong association on chromosome 2 (Fig. 1) localized to the UGT1A1 gene (Fig. 2) (significant variants, Supplementary Table 1) (QQ plot, Supplementary Fig. 2). All postbaseline analyses were adjusted for baseline bilirubin. The top variant, rs4148325 ($\beta = 0.28$ mg/dl per T allele increase; $p = 2.88 \times 10^{-41}$), had mean (SE) bilirubin levels of 0.57 (0.01) mg/dl, 0.66 (0.01) mg/dl, and 1.19 (0.05) mg/dl in the CC, CT, and TT genotypes, respectively. Variant rs4148325 is in the intronic region of the UGT1A1 gene as well as several related family members in the UGT1A locus (Fig. 2). This variant is ~4.4 kb from the well-characterized UGT1A1*28 TA repeat (rs3064744). While the UGT1A1*28 variant was not directly genotyped or imputed in our dataset, previous studies have reported rs4148325 to be in strong linkage disequilibrium with UGT1A1*28 ($r^2 = 0.88$ and $D' = 0.98$) [11]. Additionally, we confirmed that rs4148325 was the most significant variant in change from baseline analyses at Weeks 2, 12, and 24, with $p$ values ranging from $4.46 \times 10^{-10}$ to $1.16 \times 10^{-17}$. Across all analyses, there were no variants with genome-wide significant $p$ values ($<5 \times 10^{-8}$) outside of the UGT1A1 region.

Maximum bilirubin level by rs4148325 genotype was assessed in placebo + DMARD-treated patients. While significant, the effect size and $p$ value were of lesser magnitude ($\beta = 0.16$ mg/dl per allele;
We identified a strong statistical association between bilirubin elevations and UGT1A1 gene variants in sarilumab-treated RA patients. Sarilumab-treated patients homozygous for the rs4148325 T allele had significant unconjugated and conjugated bilirubin elevations; specifically sarilumab-treated patients homozygous for the T allele had maximum total bilirubin levels of 1.30 (0.05) mg/dl compared with 0.87 (0.03) mg/dl for patients receiving placebo. These values are in line with benign elevations in total bilirubin seen in Gilbert’s syndrome. Due to the strong linkage disequilibrium between the rs4148325 variant and the UGT1A1*28 allele ($r^2 = 0.88$ and $D’ = 0.98$) [11], the majority of rs4148325 TT homozygotes likely have Gilbert’s syndrome, with lower gene expression and diminished bilirubin metabolism. The highest elevations were observed in un conjugated bilirubin, consistent with decreased UGT1A1 activity in UGT1A1*28 homozygous patients. UDP-glucuronosyltransferase 1-1, the enzyme encoded by the UGT1A1 gene, is the only known enzyme responsible for bilirubin metabolism [23]. Consistent with this, our GWAS failed to identify any other loci outside of the UGT1A1 gene region associated with sarilumab-related bilirubin elevations. The variation in bilirubin levels and its association with SNPs

**DISCUSSION**

Table 2. Maximum total bilirubin in sarilumab-treated by UGT1A1 (rs4148325) genotype.

| Genotype | ≤1.5 × ULN, n (%) | >1.5 × ULN, n (%) | Total, n (%) |
|----------|------------------|------------------|------------|
| CC/CT    | 662 (90)         | 2 (11)           | 664 (88)   |
| TT       | 75 (10)          | 16 (89)          | 91 (12)    |
| Total    | 737              | 18               | 755        |

OR = 47.79 and $p = 5.67 \times 10^{-10}$.

$n$ number of participants, OR odds ratio, ULN upper limit of normal.

**Comparison of ALT, AST and ALP levels for the rs4148325 variant**

Additional analyses were performed for the rs4148325 variant comparing ALT, AST and ALP levels across each genotype group for evidence of underlying liver toxicity. Analysis of ALT elevations during the 24-week treatment periods for sarilumab-treated patients and placebo patients by rs4148325 genotype showed no evidence of association (Supplementary Fig. 5). Similarly, no association was observed for AST levels during the treatment period (Supplementary Fig. 6). None of the 16 sarilumab-treated patients with >1.5 × ULN bilirubin levels in the TT genotype group had elevations of ALT or AST >3 × ULN. The absence of ALT or AST elevations >3 × ULN in patients with the TT genotype suggests there was no underlying liver toxicity during treatment. Similarly, no significant association was observed between ALP elevations and rs4148325 in sarilumab-treated patients with a $p$ value of 0.89.

**Fig. 3 Maximum total bilirubin level (mg/dl) by UGT1A1 (rs4148325) genotype and treatment (placebo + DMARD and sarilumab + DMARD).** Boxplots of the maximum bilirubin level by genotype are shown.

**Fig. 4 Baseline total bilirubin levels (mg/dl) by UGT1A1 (rs4148325) genotype for all patients (placebo + DMARD and sarilumab + DMARD arms are combined).** Boxplots of the baseline bilirubin level by genotype are shown. Treatment arms were combined to assess bilirubin levels pre-treatment.

$p = 9.25 \times 10^{-14}$ than the effects observed in sarilumab + DMARD-treated patients. The genotypic means (SE) were comparatively lower: 0.46 (0.02) mg/dl; 0.52 (0.02) mg/dl and 0.87 (0.06) mg/dl in the CC, CT, and TT genotypes, respectively. The persistent association of bilirubin and rs4148325 genotype in the absence of sarilumab treatment may be due to the underlying DMARD use. A comparison of maximum bilirubin levels during the clinical trial period, stratified by treatment arm, is shown in Fig. 3.

To further evaluate the association between rs4148325 and bilirubin levels, an analysis at baseline in all patients was conducted. This also demonstrated a strong association (Fig. 4; $p = 3.59 \times 10^{-42}$, $\beta = 0.11$ mg/dl per allele). Mean (SE) baseline bilirubin was 0.33 (0.007), 0.38 (0.007), and 0.60 (0.02) mg/dl in the CC, CT, and TT genotypes, respectively.

To assess the potential clinical impact of the variability in bilirubin level by rs4148325 genotype, analysis of bilirubin elevations with respect to ULN were conducted. By study entry criteria, no patients had bilirubin elevations in excess of 1.5 × ULN at baseline. Additionally, no elevations >1.5 × ULN in bilirubin were observed in placebo + DMARD-treated patients, while 18 sarilumab-treated patients had bilirubin elevations >1.5 × ULN. In the binary analysis of maximum total bilirubin among sarilumab-treated patients, the TT genotype was significantly associated with bilirubin elevations (Table 2; odds ratio 47.79; $p = 5.67 \times 10^{-10}$). This finding was confirmed with a Fisher’s exact test ($p = 1.14 \times 10^{-7}$). In total, 18 of 755 (2.4%) of sarilumab-treated patients had bilirubin elevations >1.5 × ULN, and of those, 16 of 18 (89%) were homozygous for the T allele, while only two patients (11%) were in either the CC or CT genotype group. Only 2 of 664 (0.3%) CC or CT patients had bilirubin elevations >1.5 × ULN compared to 16 of 91 (17.6%) of TT patients with bilirubin elevations >1.5 × ULN (Table 2).

Longitudinal analysis of bilirubin levels measured at several time points during the 24-week treatment periods demonstrated differences between genotype groups over the course of the study (Fig. 5). Patients treated with sarilumab + DMARD in the TT genotype group showed the greatest increase in bilirubin levels over time ($\beta = 0.09$ mg/dl; $p = 1.07 \times 10^{-45}$; treatment interaction $p = 0.03$). This analysis was extended to measurements in both unconjugated and conjugated bilirubin (Supplementary Fig. 3) and conjugated bilirubin (Supplementary Fig. 4). The increases in unconjugated bilirubin were significant ($\beta = 0.08$ mg/dl; $p = 6.76 \times 10^{-45}$) and greater than increases in conjugated bilirubin, suggesting that most of the increase in total bilirubin is unconjugated. However, conjugated bilirubin levels were also increased in the TT genotype group ($\beta = 0.01$ mg/dl; $p = 4.39 \times 10^{-30}$).

We also observed 29 carriers of the UGT1A1*6 allele (G71R). This variant has been shown in previous studies to have decreased bilirubin metabolism [23]. Consistent with this, we observed 28 carriers of the $r^2 = 0.88$ and $D’ = 0.98$ [11], the majority of rs4148325 TT homozygotes likely have Gilbert’s syndrome, with lower gene expression and diminished bilirubin metabolism. The highest elevations were observed in un conjugated bilirubin, consistent with decreased UGT1A1 activity in UGT1A1*28 homozygous patients. UDP-glucuronosyltransferase 1-1, the enzyme encoded by the UGT1A1 gene, is the only known enzyme responsible for bilirubin metabolism [23]. Consistent with this, our GWAS failed to identify any other loci outside of the UGT1A1 gene region associated with sarilumab-related bilirubin elevations. The variation in bilirubin levels and its association with SNPs.
belonging to UGT1A1 (rs4148325) and SCLO1B1 (rs4149056) loci is reported in previous studies [24]. The top variant rs4149056 in SLC01B1 on chromosome 12 had a p value of 0.1 in this study. Increase in conjugated bilirubin could be due to treatment with DMARD (methotrexate). Previous studies of methotrexate use in pediatric leukemia have also shown increase in total and direct bilirubin [25].

Our findings are consistent with previous observations in patients treated with tocilizumab, another IL-6Rα inhibitor, and suggest that IL-6 pathway inhibition leads to decreased UDP-glucuronosyltransferase 1-1 activity in Gilbert’s syndrome patients [11, 12]. The definitive mechanism by which blocking IL-6 signaling leads to the inhibition or saturation of UDP-glucuronosyltransferase 1-1 activity is unclear, but the parallel findings in studies of two IL-6Rα inhibitors suggest a class effect. As neither sarilumab nor tocilizumab are directly glucuroni-
dated by UDP-glucuronosyltransferase 1-1, inhibition of the IL-6 pathway may indirectly affect levels of the UGT1A1 transcript. Previous studies have shown that IL-6 can affect UGT1A1 mRNA levels in rat hepatocytes [26]. An alternative hypothesis is that IL-6R inhibition corrects hepcidin induced hypoferremia [27] and this increased hemoglobin turnover in patients with UGT1A1 mutations causes a corresponding increase in unconjugated bilirubin that saturates renal clearance. The exact mechanism for the increases in bilirubin for Gilbert’s syndrome patients after sarilumab treatment remains unclear and will require additional studies.

During the clinical trials, transaminase elevations occurred more frequently in sarilumab + DMARD-treated patients versus placebo+DMARD-treated patients [13]. However, the mean level of these elevations remained within the normal range, and most elevations were mild and self-limiting [8]. ALT or AST elevations >3×ULN were not observed in sarilumab-treated patients homozygous for the rs4148325 T allele with bilirubin elevations >1.5×ULN (n = 16). Consequently, no cases of Hy’s law were observed in the rs4148325 TT homozygote group, nor were any observed in the overall clinical trials for sarilumab-treated patients [10].

UGT1A1 is involved in the direct glucuronidation of a number of drugs or their metabolites, including simvastatin, ibuprofen, and irinotecan [5]. For irinotecan and atazanavir, variants in UGT1A1 have been associated with treatment-related adverse events. Patients treated with irinotecan who are homozygous for the UGT1A1*28 allele are at greater risk of developing severe neutropenia after treatment [28]. However, these adverse events are due to decreased glucuronidation and clearance of irinotecan’s active metabolite SN-38. The neutropenia observed in irinotecan-treated patients is directly related to SN-38 activity and is not related to bilirubin metabolism nor does it share any similarities with the mild bilirubin elevations observed in sarilumab-treated patients. Atazanavir treatment can cause severe hyperbilirubinemia in some patients, with 40% reporting bilirubin levels >2.5×ULN (Grade 3), and ≈4 to 8% reporting bilirubin levels ≥5×ULN (Grade 4) [7]. Hyperbilirubi-
nemia seen in atazanavir-treated patients is more common and reaches considerably higher levels than the mild elevations observed in sarilumab-treated patients. Only 2.4% of sarilumab-treated patients had bilirubin elevations >1.5×ULN and none had Grade 3 or 4 hyperbilirubinemia. Our findings suggest that most sarilumab-related increases in bilirubin levels are caused by common genetic variation in UGT1A1 and not underlying severe liver injury. Gilbert’s syndrome patients, who have preexisting lower bilirubin metabolism, are susceptible to mild elevations in serum bilirubin after sarilumab treatment. However, the incorporation of genotyping data into patient safety assessments, particularly related to bilirubin elevations, may allow for more accurate diagnosis of liver safety events for patients receiving IL-6Rα inhibitors.

Fig. 5 Change in total bilirubin level (mg/dl) over time by UGT1A1 (rs4148325) genotype in A Sarilumab + DMARD-treated patients and B Placebo + DMARD-treated patients. Functional canonical correlation analysis (FCCA) was applied to test the association between the change in total bilirubin level over time and rs4148325 genotype (Interaction: rs4148325 genotype × treatment, p = 0.03).
REFERENCES

1. Onakpoya IU, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.

2. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. 2009. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-induced-liver-injury-premarketing-clinical-evaluation.

3. Hoofnagle JH, Björnsson ES. Drug-induced liver injury—types and phenotypes. N Engl J Med. 2019;381:264–73.

4. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–54.

5. Strassburg CP. Pharmacogenetics of Gilbert’s syndrome. Pharmacogenomics. 2008;9:703–15.

6. Bosma PJ, Chowdhury JR, Bakker C, Gantila S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995;333:1171–5.

7. Gammal RS, Court MH, Hadair CE, Iwuchukwu OF, Gaur AH, Alvarezos M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and Atazanavir prescribing. Clin Pharm Ther. 2016;99:363–9.

8. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in pathological and physiological conditions. Clin Sci. 2012;122:143–59.

9. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology. 2010;49:15–24.

10. Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up. Rheumatology. 2020;59:292–302.

11. Lee JS, Wang J, Martin M, Germer S, Kenwright A, Benayed R, et al. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenet Genomics. 2011;21:365–74.

12. Mori S, Terada K, Ueki Y. Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms. Mod Rheumatol. 2012;22:515–23.

13. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarz M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424–37.

14. Fleischmann R, van Adelsberg J, Lin Y, Castellar-Pinheiro GD, Brzezicki J, Hrycay P, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69:277–90.

15. Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology. 2019;58:849–58.

16. Das S, Forer L, Schonher S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48:1284–7.

17. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.

18. Purcell SM, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.

19. Lin N, Zhu Y, Fan R, Xiong M. A quadratically regularized functional canonical correlation analysis for identifying the global structure of pleiotropy with NGS data. PLoS Comput Biol. 2017;13:e1005788.

20. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8:53.

21. Kotake S, Sato K, Kim K, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88–95.

22. Chang CC, Chou CC, Teller LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.

23. Barbarino JM, Haider CE, Klein TE, Altman RB, PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet Genomics. 2014;24:177–83.

24. Johnson JD, Kavoussi M, Smith AV, Chen MH, Dehghan A, Aspelund T, et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet. 2009;18:2700–10.

25. Bordbar M, Shakibazad N, Fattahi M, Haghsahan S, Honar N. Effect of urso-deoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. Turk J Gastroenterol. 2018;29:203–9.

26. Strasser SI, Mashford ML, Desmond PV. Regulation of uridine diphosphate glucuronosyltransferase during the acute-phase response. J Gastroenterol Hepatol. 1998;13:88–94.

27. Ganz T. Anemia of Inflammation. N Engl J Med. 2019;381:1148–57.

28. Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol. 2010;5:209–17.

ACKNOWLEDGEMENTS

The research was funded by Sanofi Genzyme and Regeneron, and the authors gratefully acknowledge the contributions of all study investigators. The authors also thank all patients for their participation. Editorial assistance was provided by Peter Tran (Adedphi Communications Ltd, Macclesfield, UK), Aishwarya Kulkarni, Geetika Kainthla and Rakesh Ojha (Sanofi Genzyme), and was funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. in accordance with Good Publication Practice (GPP3).

AUTHOR CONTRIBUTIONS

NL, AD, A Boyapati, and CP conceived and planned the study. NL and AD conducted the statistical analysis. JP, AL, JGR, and JO were involved in data generation. NL, AD, and CP wrote the manuscript with input and comments from all authors (AB, JDH, SH, NT, MCN, JP, AL, JGR, JO, ARS, GA, and A Baras).

COMPETING INTERESTS

NL, AD, A Boyapati, JDH, SH, MCN, AL, JGR, JO, ARS, GA, and A Baras, and CP are employees of Regeneron Pharmaceuticals, Inc., and may hold stock and/or stock options in the company. JP is a former employee of Regeneron Pharmaceuticals, Inc., and may hold stock and/or stock options in the company, and is currently employed by DNAnexus. NT is an employee of Sanofi and may hold stock and/or stock options in the company.

ADDITIONAL INFORMATION

Supplementary information

The online version contains supplementary material available at https://doi.org/10.1038/s41397-022-00269-5.

Correspondence and requests for materials should be addressed to Charles Paulding.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

The Pharmacogenomics Journal (2022) 22:160 – 165

SPRINGER NATURE

165